AbbVie | ABBV - Betriebsaufwand

Aktienkurs
198.71
Täglich Wechseln
-2.24 -1.11%
Monatlich
-4.09%
Jährlich
6.80%
Q2 Prognose
194.46




Betriebsaufwand Veränderung Datum
AbbVie USD 10.81B 13.45B 2025-12
Abbott USD 9.31B 104M 2026-03
ALKERMES USD 326.44M 1.41B 2025-12
Amgen USD 5.9B 773M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Infinity Pharmaceuticals USD 10.7M 1.54M 2023-06
J&J USD 17.44B 1.53B 2026-03
Medtronic USD 7.28B 16M 2025-12
Merck USD 10.16B 558M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 61M 2025-12
Pacira USD 193.68M 27.32M 2025-12
Perrigo USD 1.03B 75.3M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
UCB EUR 2.96B 196M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Zoetis USD 1.55B 3.85B 2025-12